相关实验视频
Updated: May 11, 2026
08:31
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
10.9K
阴离子基乙纤维素纳米复合物和RANK siRNA / Zoledronate联合交付系统用于骨质细胞抑制
Sohyun Lee1, Seoyeon Park1, Tae-Il Kim1,2
1Department of Agriculture, Forestry and Bioresources, College of Agriculture and Life Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
Pharmaceutics
|January 8, 2025
概括
基于乙纤维素 (HEC) 的新纳米复合物有效抑制骨质细胞活性. 这些HECP2k/(RANK siRNA + Zol) 复合体通过减少骨质细胞分化和促进亡,显示出治疗骨疾病的潜力.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 分子生物学分子生物学
背景情况:
- 骨质细胞过度活跃会导致骨疾病.
- 目前针对骨质细胞相关疾病的治疗方法在siRNA输送和药物生物可用性方面面临挑战.
- 研究了用聚乙烯胺2k (PEI2k) 修饰的乙烯纤维素 (HEC) 形成HECP2k.
研究的目的:
- 开发基于HECP2k的纳米复合物,用于联合输送核因子k-B (RANK) siRNA和zoledronate (Zol) 的受体激活剂.
- 评估这些纳米复合物的骨质细胞抑制潜力.
- 克服低siRNA转染效率和Zol生物可用性的局限性.
主要方法:
- 通过简单的混合来制备HECP2k/(RANK siRNA + Zol) 纳米复合体.
- 描述包括尺寸,泽塔潜力和细胞吸收评估.
- 实验室试验,如酸耐酸酶 (TRAP) 试验和qPCR被用于评估骨质细胞抑制和基因表达变化.
主要成果:
- 成功形成了具有最佳尺寸 (~200 nm) 和细胞吸收的泽塔电位 (~20 mV) 的纳米复合体.
- 已证明具有高的内分体缓冲能力,表明有效的内分体逃逸.
- 与PEI25k和HECP2k复合体相比,表现出较低的细胞毒性 (>90%的细胞活力) 和更高的传染效率.
- 显著抑制TRAP活性 (~50%) 和调节骨质细胞基因表达,包括FAS基因表达增加16倍.
结论:
- HECP2k/(RANK siRNA + Zol) 纳米复合物在抑制骨质细胞分化和活性方面是有效的.
- 兰克siRNA和Zol的组合作用诱导骨质细胞的亡.
- 这些纳米复合体显示出作为治疗骨相关疾病的治疗策略的希望.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...